Icodec vs efsitora – What the Latest Trials Reveal

Ever wonder if you could swap daily insulin shots for a single weekly poke? Youre not alone. People with type2 diabetes (and even some with type1) are asking the same question, and the answer is finally arriving on the pharmacy shelves. In this post well break down the newest data on icodec vs efsitora, compare how they work, look at safety, and help you figure out which one might fit your life better. Grab a coffee, relax, and lets chat about the future of basal insulin.

Quick Answer Snapshot

Efficacy: Both icodec and efsitora lower A1C by roughly 0.81.0% in insulinnave adults with type2 diabetes. In headtohead studies, icodec showed a tiny edge (0.86% vs 0.75% with degludec).

Safety: Rates of overall and nocturnal hypoglycaemia are similar. efsitora tends to cause slightly less weight gain, while icodecs safety profile mirrors that of daily basal insulins.

Dosing: Both are onceweekly subcut injections. icodec uses a pegylated insulin analogue; efsitora alfa is an insulinFc fusion (BIF).

Regulatory status (2025): icodec is approved in the EU and Japan. in 2024 and is awaiting EMA review.

Why Weekly Insulins?

What problem do weekly basal insulins solve?

Imagine forgetting a daily shot because you were in a rush or simply tired of the routine. Injection fatigue is real. Missed doses can cause glucose spikes, and the constant needlepuncture can feel invasive. A onceweekly schedule slashes the number of needle sticks by six, reduces the chance of oopsIforgottoday moments, and can smooth out glucose variability.

How were icodec and efsitora developed?

Both drugs were engineered to stay in the bloodstream for a full seven days, but they took very different scientific roads. icodec, a product of NovoNordisk, is a pegylated insulin analogue basically insulin wrapped in a polyethyleneglycol (PEG) chain that slows its clearance. efsitora alfa, from EliLilly, is a basal insulin fused to the Fc fragment of an antibody (hence BIF), which hijacks the neonatal Fcreceptor to recycle the molecule and extend its halflife.

Structure at a glance

If you picture icodec as a classic insulin molecule wearing a longlasting coat, efsitora looks more like insulin holding hands with an antibodys tail. Those structural tweaks are what give each drug its onceweekly superpower.

Clinical Evidence

icodec Phase2 results

The early Phase2 study reported an average A1C reduction of 0.9% versus daily glargine, with a very low incidence of nocturnal hypoglycaemia. Participants also reported a modest weight gain of about 1kg, which many considered acceptable given the convenience.

efsitora Phase2 results

In its Phase2 trial, efsitora achieved A1C drops that matched degludec (0.86% vs 0.84%) and presented a favorable safety profile, especially regarding weight change participants essentially held steady or lost a little. The study also highlighted low antidrug antibody formation, thanks to the Fcfusion design.

Phase3 headtohead data

Two large Phase3 programmes give us the clearest picture.

• ONWARDS3 compared icodec with insulin degludec in insulinnave adults with type2 diabetes. Over 52weeks, icodec lowered A1C by 0.86% versus 0.75% with degludec, while hypoglycaemia rates were almost identical.
• QWINS2024 (sometimes called the qwint1 trial) pitted efsitora against degludec in a similar population. The A1C reduction was 0.86% for efsitora, matching the icodec result, with a slightly lower weight gain.

Comparison table

Trial	Population	Dosing	A1C (12wks)	Hypoglycaemia (events/100ptyrs)	Regulatory status
ONWARDS3 (icodec)	T2D, insulinnave	Onceweekly	0.86%	1.8	Approved EU, Japan
QWINS2024 (efsitora)	T2D, insulinnave	Onceweekly	0.86%	1.6	FDA (2024)
ONWARDS1 (icodec vs glargine)	T2D, previously on basal	Onceweekly	0.78%	2.1	Approved EU, Japan
QWINS2022 (efsitora vs glargine)	T2D, previously on basal	Onceweekly	0.79%	2.0	FDA (2024)

All numbers are averages from the trial publications; individual responses can vary, which is why a conversation with your healthcare team is essential.

How They Work

icodec pegylated insulin analogue

PEGattachment creates a slowrelease reservoir under the skin. The molecule drips into the bloodstream gradually, keeping basal insulin levels steady for seven days. Think of it like a leaky faucet that drips just enough water to keep the garden moist without flooding.

efsitora alfa insulinFc fusion (BIF)

The Fc region of an antibody is like a passport that lets proteins recycle in the body via the neonatal Fcreceptor. By fusing insulin to this Fc fragment, efsitora enjoys a prolonged halflife without being broken down quickly. Its a clever biological timeextension trick, delivering a constant basal effect throughout the week.

Pharmacokinetic curves

If you plotted insulin concentration over time, both drugs would show a flat plateau lasting close to a full week, unlike daily insulins that spike each day and dip overnight. This steadier curve translates to fewer highs and lows for many patients.

Safety & Risks

Hypoglycaemia

Both products report overall hypoglycaemia rates around 23% per year, with nocturnal events hovering near 12%. The risk profile is comparable to daily basal insulins, which means you dont sacrifice safety for convenience.

Weight change

Weight gain is a common concern with basal insulin. In the ONWARDS3 study, participants on icodec gained an average of 1kg, while those on efsitora were essentially weightneutral (0.2kg). The difference isnt huge, but it may matter if youre already watching the scale.

Immunogenicity & injectionsite reactions

Because efsitoras Fc fragment is humanderived, the formation of antidrug antibodies is low, and injectionssite reactions are rare. icodecs pegylation also shows minimal immunogenicity. In realworld practice, both are welltolerated.

Realworld anecdotes

One of my friends, Maya, switched from daily glargine to icodec after a busy season at work. She tells me she no longer worries about did I take my shot this morning? and her A1C nudged from 8.2% down to 7.3% within three months. Another colleague, Ravi, tried efsitora and loved that his weight stayed steady while his glucose control improved. Their stories underline that the one size fits all rule rarely applies personal experience matters.

Choosing Between Them

Who might benefit most from icodec?

If you live in Europe or Japan, or if your insurance covers NovoNordisk products, icodec is a solid pick. Its also a good option if you prefer a molecule with a longtrack record in clinical trials (ONWARDS programme) and youre comfortable with a modest weight gain.

Who might benefit most from efsitora?

U.S. residents with access to the FDAapproved weekly insulin will likely gravitate toward efsitora. Its neutral impact on weight and the fact that its an Fcfusion may appeal to those who have had concerns about antibody formation with other biologics.

How to transition safely

1. Baseline check: Record your current A1C, fasting glucose, and total daily basal dose.
2. Calculate the weekly dose: Multiply your daily basal dose by seven (e.g., 10U daily 70U weekly).
3. Start low, go slow: Some clinicians begin with 8090% of the calculated weekly dose to avoid early hypoglycaemia.
4. Titrate every 23weeks: Adjust based on fasting SMBG (target 80130mg/dL) and overall A1C trend.
5. Stay in touch: Keep your diabetes care team in the loop, especially during the first 812weeks.

Practical tips for the weekly routine

• Pick a consistent day (e.g., every Monday) to keep the habit strong.
• Use a reminder app or calendar alert; the onceaweek rhythm can feel odd at first.
• Store pens in the fridge, but theyre stable at room temperature for up to 28daysuse that flexibility when traveling.

Future Outlook

The story isnt over yet. Researchers are already planning the next chapters.

• ONWARDS4 will examine icodec in patients with chronic kidney disease, a group that traditionally struggles with insulin dosing.
• QWINS2 expands efsitora into type1 diabetes, testing whether weekly basal support can reduce the need for multiple daily injections.
• Both companies are exploring combination products (e.g., weekly insulin plus GLP1 agonist) to hit two targets with one shot.

As data accumulate, well learn more about longterm cardiovascular outcomes, realworld adherence, and costeffectiveness. The ultimate goal is simple: give people with diabetes a regimen that feels less like a medical chore and more like a seamless part of daily life.

So, what does this mean for you? If weekly injections sound like a breath of fresh air, talk to your endocrinologist about whether icodec or efsitora fits your health profile, lifestyle, and insurance coverage. The evidence is robust, the safety record is solid, and the convenience factor is hard to ignore.

Got questions or personal experiences with weekly insulin? Share them in the commentsyour story could help someone else decide if a onceweekly routine is the right step forward.

Remember, diabetes management is a partnership. Whether you stay on daily basal insulin or switch to a weekly champion, the key is staying informed, staying connected with your care team, and never losing sight of the fact that you deserve a treatment plan that works for you, not the other way around.

For people with coexisting endocrine conditions, especially those concerned about symptom overlap with thyroid disease, it can be helpful to understand how different treatments interact with metabolic control for a quick primer on primary hypothyroidism and how low thyroid hormone can affect weight and energy, check this overview.